Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
The vaccines developed for COVID-19 have been immensely successful in preventing infection and symptomatic disease. However, their distribution and administration has been, and continues to be, limited by supply.
In March 2021, Canada's advisory committee on vaccines recommended that the interval between first and second doses be extended from three weeks to up to four months. This strategic recommendation aimed to accelerate the proportion of Canadians receiving their first dose in the face of vaccine shortages.
At the time, the effects of changing the dosing interval were not well understood. A new study in Nature Immunology from the Toronto General Hospital Research Institute and UHN's Ajmera Transplant Centre that was led by clinician-investigator Dr. Deepali Kumar and Senior Scientist Dr. Atul Humar shows that extending the dosing interval for the Pfizer-BioNTech vaccine not only maintains but actually enhances the vaccine's ability to trigger immune responses.
The study examined the effects of the interval between doses in 93 healthcare workers who received the Pfizer-BioNTech vaccine. Participants received their second dose after either a short interval (i.e., three to six weeks) or a longer interval (i.e., eight to 16 weeks).
"Because healthcare workers were prioritized for vaccination and many of them were able to receive their doses according to the original schedule, they were an ideal population for our study," says Dr. Humar.
One month after the healthcare workers had received their second shot, blood work was done to assess the concentration of neutralizing antibodies – molecules produced by the immune system that target the SARS-CoV-2 virus and prevent it from infecting cells.
While all participants had robust antibody levels, the individuals who received their second vaccine after the longer interval had higher antibody levels.
To determine how effective these antibodies were at neutralizing the virus, the researchers mixed the participants' antibody samples with live SARS-CoV-2 virus. They found that samples from the group with the longer vaccination interval could neutralize more virus versus individuals with the short vaccination interval. These findings were consistent for the original virus as well as its Alpha, Beta and Delta variants.
"The findings show that Canada's strategy for delaying the second dose was likely quite helpful in fighting against COVID-19 variants," says Dr. Kumar. "This will inform ongoing vaccination efforts, especially within the many regions around the world that are still waiting for access to vaccines.
"We are also continuing to track our study participants to investigate long-term differences in immunity."